• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    (CTMX) - Analyzing CytomX Therapeutics's Short Interest

    6/5/24 1:00:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email

    CytomX Therapeutics's (NYSE:CTMX) short percent of float has risen 143.23% since its last report. The company recently reported that it has 8.75 million shares sold short, which is 11.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    CytomX Therapeutics Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for CytomX Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing CytomX Therapeutics's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, CytomX Therapeutics's peer group average for short interest as a percentage of float is 6.21%, which means the company has more short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $CTMX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    1/20/2026$10.00Buy
    Guggenheim
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    9/17/2025$3.50Overweight
    Barclays
    7/31/2025$7.00Outperform
    Oppenheimer
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on CytomX Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $6.00

    9/22/25 8:30:10 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on CytomX Therapeutics with a new price target

    Barclays resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $3.50

    9/17/25 7:59:04 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytomX Therapeutics to Present at Upcoming February Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be found on the Events and Presentations page of CytomX's website at www.cytomx.com. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharm

    2/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Announces Business Update and Company Milestones for 2026

    - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ

    1/8/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/5/26 1:20:38 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/7/25 11:13:45 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by CytomX Therapeutics Inc.

    144 - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/6/25 9:08:33 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Lester Rachael was granted 20,000 shares (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:28:36 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chu Yu-Waye was granted 75,000 shares, increasing direct ownership by 55% to 210,725 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:27:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Scientific Officer Belvin Marcia was granted 60,000 shares, increasing direct ownership by 22% to 332,252 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:25:27 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 3:03:21 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

    3/21/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics Announces Business Update and Company Milestones for 2026

    - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ

    1/8/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

    - CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced third quarter 2025 financial results and provided a business update. "CytomX continued to execute against its pipeline priorities this quarter,

    11/6/25 4:10:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior t

    10/30/25 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care